Current and future options in cholesterol lowering treatments

被引:6
作者
Elis, Avishay [1 ,2 ]
机构
[1] Beilinson Med Ctr, Rabin Med Ctr, Dept Internal Med C, Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel
关键词
Statins; Ezetimibe; Anti PCSK9 monoclonal antibodies; Inclisiran; Bempedoic acid; Lipid lowering agents; DENSITY-LIPOPROTEIN CHOLESTEROL; DRUG-INTERACTIONS; LDL CHOLESTEROL; REDUCING LIPIDS; SAFETY; EFFICACY; STATINS; ROSUVASTATIN; EZETIMIBE; PHARMACOKINETICS;
D O I
10.1016/j.ejim.2023.02.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The relative risk reduction of cardiovascular events is proportional to the absolute reduction in LDL-C levels, the primary target of therapy, no matter the way of reduction. During the last decades, the therapeutic regimens for reducing the LDL-C levels have been immerged and improved, with favorable effects on the atherosclerotic process and clinical benefits of various cardiovascular outcomes. From a practical view of point, this review is focusing only on the current available lipid lowering agents: statins, ezetimibe, anti PCSK9 monoclonal antibodies, the small interfering RNA (siRNA) agent, Inclisiran, and Bempedoic acid. The recent changes in lipid lowering regimens, including the early combination of lipid lowering agents and "Low LDL-C" levels <30 mg/dL for high/very high cardiovascular risk patients will also be discussed.
引用
收藏
页码:1 / 5
页数:5
相关论文
共 72 条
[1]   Lipid-lowering efficacy of atorvastatin [J].
Adams, Stephen P. ;
Tsang, Michael ;
Wright, James M. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (03)
[2]  
Adams SP, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008226.pub2, 10.1002/14651858.CD010254.pub2]
[3]   Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer - Insights from large randomized statin trials [J].
Alsheikh-Ali, Alawi A. ;
Maddukuri, Prasad V. ;
Han, Hui ;
Karas, Richard H. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (05) :409-418
[4]  
[Anonymous], EZ ZET US PREGN
[5]  
[Anonymous], 2022, FOURIER OLE STUD HOT
[6]  
[Anonymous], 2011, DAILYMED 0126
[7]   Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis [J].
Awad, Kamal ;
Serban, Maria-Corina ;
Penson, Peter ;
Mikhailidis, Dimitri P. ;
Toth, Peter P. ;
Jones, Steven R. ;
Rizzo, Manfredi ;
Howard, George ;
Lip, Gregory Y. H. ;
Banach, Maciej .
JOURNAL OF CLINICAL LIPIDOLOGY, 2017, 11 (04) :972-985
[8]   Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].
Baigent, C. ;
Blackwell, L. ;
Emberson, J. ;
Holland, L. E. ;
Reith, C. ;
Bhala, N. ;
Peto, R. ;
Barnes, E. H. ;
Keech, A. ;
Simes, J. ;
Collins, R. .
LANCET, 2010, 376 (9753) :1670-1681
[9]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[10]   Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study [J].
Ballantyne, Christie M. ;
Banach, Maciej ;
Mancini, G. B. John ;
Lepor, Norman E. ;
Hanselman, Jeffrey C. ;
Zhao, Xin ;
Leiter, Lawrence A. .
ATHEROSCLEROSIS, 2018, 277 :195-203